| Literature DB >> 35630396 |
Po-Chun Chuang1,2, Wen-Hao Lin3, Yi-Chun Chen4, Chun-Chih Chien2,5, I-Min Chiu1,2, Tein-Shun Tsai6.
Abstract
Wound infections after venomous snakebites are clinically important. Information regarding the nature and antibiotic susceptibilities of snake oral bacterial flora could support empiric antibiotic therapy. Wild venomous snakes were collected from southern Taiwan: a total of 30 each of Bungarus multicinctus, Naja atra, Protobothrops mucrosquamatus, and Trimeresurus stejnegeri; 3 Deinagkistrodon acutus; and 4 Daboia siamensis. The species and antibiotic susceptibilities of their oral bacteria were determined. Aerobic gram-negative bacteria, especially Pseudomonas aeruginosa and Proteus vulgaris, were the most abundant. Proteus vulgaris were more abundant in B. multicinctus, N. atra, and P. mucrosquamatus than in T. stejnegeri (40%, 43.3%, and 40% vs. 13.3%, respectively). The gram-negative species were less susceptible to first- and second-generation cephalosporins and ampicillin-sulbactam than to third-generation cephalosporins, fluoroquinolones, carbapenems, or piperacillin-tazobactam. The most abundant aerobic gram-positive species cultured was Enterococcus faecalis, which was more abundant in N. atra than in other snakes (p < 0.001) and was highly susceptible to ampicillin, high-level gentamicin, penicillin, teicoplanin, and vancomycin. Bacteroides fragilis and Clostridium species were the most common anaerobic bacteria. The anaerobic organisms were highly susceptible to metronidazole and piperacillin. As a reference for empiric antimicrobial therapy, third-generation cephalosporins, fluoroquinolones, carbapenems, or piperacillin-tazobactam can be initiated in venomous snakebites wound infections.Entities:
Keywords: antibiotic susceptibility; elapids; neglected diseases; pit vipers; snakebites; wound infection
Year: 2022 PMID: 35630396 PMCID: PMC9147925 DOI: 10.3390/microorganisms10050951
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Bacteria associated with secondary wound infection after snakebite and reported in the literature [5,11,13,18,22,23].
| Aerobic Bacteria | Anaerobic Bacteria | |
|---|---|---|
| Gram-Positive | Gram-Negative | |
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
Figure 1The percentages (a) and numbers (b) of isolated potentially infectious bacteria found in the oral cavities of venomous snakes.
Bacteria identified from the oral cavities of six venomous snake species.
| BM ( | DA ( | DS ( | NA ( | PM ( | TS ( | ||
|---|---|---|---|---|---|---|---|
|
| |||||||
| 15 (50%) | 2 (66.7%) | 2 (50%) | 17 (56.7%) | 17 (56.7%) | 14 (46.7%) | 0.963 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 0 (0%) | 1.000 | |
| 3 (10%) | 0 (0%) | 0 (0%) | 7 (23.3%) | 2 (6.7%) | 1 (3.3%) | 0.228 | |
| 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 0.108 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 1.000 | |
| 1 (3.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 1.000 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 1.000 | |
| 7 (23.3%) | 0 (0%) | 1 (25%) | 5 (16.7%) | 7 (23.3%) | 5 (16.7%) | 0.935 | |
| 17 (56.7%) | 1 (33.3%) | 3 (75%) | 21 (70%) | 13 (43.3%) | 13 (43.3%) | 0.195 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 1.000 | |
|
| |||||||
| 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 1 (3.3%) | 1 (3.3%) | 0.158 | |
| 1 (3.3%) | 1 (33.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (13.3%) | 0.029 | |
| 21 (70%) | 1 (33.3%) | 2 (50%) | 30 (100%) | 7 (23.3%) | 11 (36.7%) | <0.001 | |
| 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 4 (13.3%) | 0 (0%) | 0.012 | |
|
| |||||||
| 5 (16.7%) | 0 (0%) | 0 (0%) | 7 (23.3%) | 5 (16.7%) | 5 (16.7%) | 0.972 | |
| 8 (26.7%) | 1 (33.3%) | 1 (25%) | 1 (3.3%) | 3 (10%) | 6 (20%) | 0.067 | |
| 3 (10%) | 0 (0%) | 0 (0%) | 6 (20%) | 3 (10%) | 14 (46.7%) | 0.006 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 1 (3.3%) | 1.000 | |
| 1 (3.3%) | 1 (33.3%) | 0 (0%) | 1 (3.3%) | 6 (20%) | 7 (23.3%) | 0.035 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 1.000 | |
| 1 (3.3%) | 0 (0%) | 0 (0%) | 2 (6.7%) | 0 (0%) | 1 (3.3%) | 0.922 | |
| 6 (20%) | 1 (33.3%) | 0 (0%) | 1 (3.3%) | 5 (16.7%) | 1 (3.3%) | 0.086 | |
| 0 (0%) | 0 (0%) | 1 (25%) | 1 (3.3%) | 1 (3.3%) | 0 (0%) | 0.158 | |
| 1 (3.3%) | 0 (0%) | 1 (25%) | 2 (6.7%) | 2 (6.7%) | 0 (0%) | 0.287 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 0 (0%) | 1.000 | |
| 12 (40%) | 2 (66.7%) | 0 (0%) | 13 (43.3%) | 12 (40%) | 4 (13.3%) | 0.029 | |
| 1 (3.3%) | 0 (0%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.108 | |
| 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 1.000 | |
| 17 (56.7%) | 2 (66.7%) | 2 (50%) | 17 (56.7%) | 19 (63.3%) | 16 (53.3%) | 0.999 | |
| 1 (3.3%) | 0 (0%) | 0 (0%) | 4 (13.3%) | 2 (6.7%) | 0 (0%) | 0.374 | |
Abbreviations: BM, Bungarus multicinctus; DA, Deinagkistrodon acutus; DS, Daboia siamensis; NA, Naja atra; PM, Protobothrops mucrosquamatus; TS, Trimeresurus stejnegeri.
Figure 2The percentages of the five most common organisms in the oral cavities of (a) Bungarus multicinctus, (b) Naja atra, (c) Protobothrops mucrosquamatus, and (d) Trimeresurus stejnegeri.
Antibiotic susceptibilities of bacteria isolated from oral cavities of snakes.
| Antibiotics (MIC, mcg/mL) | CLI (2) | MTZ (8) | PEN (10 units) | PIP (100) | SAM (10/10) | ||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| 63 (94%) | 67 (100%) | 1 (1.5%) | 62 (92.5%) | 24 (35.8%) | |||||
| 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | 1 (100%) | |||||
| 12 (92.3%) | 13 (100%) | 0 (0%) | 13 (100%) | 12 (92.3%) | |||||
| 1 (50%) | 2 (100%) | 0 (0%) | 2 (100%) | 2 (100%) | |||||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | |||||
| 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | |||||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | |||||
| 24 (96%) | 25 (100%) | 25 (100%) | 25 (100%) | 25 (100%) | |||||
| 68 (100%) | 68 (100%) | 66 (97.1%) | 68 (100%) | 67 (98.5%) | |||||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | |||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| 3 (100%) | 3 (100%) | 2 (66.7%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | |||
| 6 (100%) | 6 (100%) | 6 (100%) | 6 (100%) | 1 (16.7%) | |||||
| 72 (100%) | 72 (100%) | 72 (100%) | 72 (100%) | 72 (100%) | |||||
| 3 (60%) | 3 (60%) | 3 (60%) | 3 (60%) | 5 (100%) | 5 (100%) | 5 (100%) | |||
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||
| 23 (95.8%) | 24 (100%) | 24 (100%) | 24 (100%) | 24 (100%) | |||||
| 20 (100%) | 18 (90%) | 19 (95%) | 16 (80%) | 20 (100%) | |||||
| 26 (100%) | 26 (100%) | 2 (7.7%) | 26 (100%) | 26 (100%) | 26 (100%) | ||||
| 2 (100%) | 2 (100%) | 1 (50%) | 1 (50%) | 2 (100%) | 2 (100%) | 2 (100%) | |||
| 16 (100%) | 15 (93.8%) | 15 (93.8%) | 15 (93.8%) | 15 (93.8%) | 16 (100%) | ||||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | ||||
| 4 (100%) | 4 (100%) | 1 (25%) | 3 (75%) | 4 (100%) | 4 (100%) | 4 (100%) | |||
| 14 (100%) | 11 (78.6%) | 7 (50%) | 13 (92.9%) | 13 (92.9%) | 14 (100%) | 14 (100%) | |||
| 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | 3 (100%) | |||||
| 6 (100%) | 6 (100%) | 2 (33.3%) | 5 (83.3%) | 6 (100%) | 5 (83.3%) | 6 (100%) | |||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | ||||
| 43 (100%) | 43 (100%) | 1 (2.3%) | 3 (7%) | 42 (97.7%) | 42 (97.7%) | 43 (100%) | |||
| 2 (100%) | 1 (50%) | 1 (50%) | 2 (100%) | 2 (100%) | 2 (100%) | 2 (100%) | |||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | ||||
| 73 (100%) | 73 (100%) | 73 (100%) | 73 (100%) | 73 (100%) | |||||
| 7 (100%) | 7 (100%) | 6 (85.7%) | 6 (85.7%) | 6 (85.7%) | |||||
|
|
|
|
|
|
|
|
|
| |
| 21 (87.5%) | 22 (91.7%) | 23 (95.8%) | 24 (100%) | 24 (100%) | |||||
| 4 (20%) | 20 (100%) | 20 (100%) | |||||||
| 26 (100%) | 26 (100%) | 25 (96.2%) | 5 (19.2%) | 26 (100%) | |||||
| 2 (100%) | 2 (100%) | 2 (100%) | 1 (50%) | 2 (100%) | |||||
| 16 (100%) | 16 (100%) | 15 (93.8%) | 5 (31.3%) | 16 (100%) | |||||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | |||||
| 4 (100%) | 4 (100%) | 4 (100%) | 3 (75%) | 4 (100%) | |||||
| 14 (100%) | 13 (92.9%) | 14 (100%) | 14 (100%) | 13 (92.9%) | |||||
| 3 (100%) | 3 (100%) | 3 (100%) | 1 (33.3%) | 3 (100%) | |||||
| 6 (100%) | 6 (100%) | 6 (100%) | 5 (83.3%) | 6 (100%) | |||||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | |||||
| 43 (100%) | 43 (100%) | 43 (100%) | 43 (100%) | 43 (100%) | |||||
| 2 (100%) | 2 (100%) | 1 (50%) | 2 (100%) | 2 (100%) | |||||
| 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) | ||||||
| 73 (100%) | 73 (100%) | 73 (100%) | 73 (100%) | 71 (97.3%) | 73 (100%) | ||||
| 7 (100%) | 7 (100%) | 7 (100%) | 6 (85.7%) | ||||||
Abbreviations: MIC, minimal inhibitory concentration; CLI, clindamycin; MTZ, metronidazole; PEN, penicillin; PIP, piperacillin; SAM, ampicillin-sulbactam; AMP, ampicillin; ERY, erythromycin; GEN, gentamicin; OXA, oxacillin; SXT, sulfonamides-trimethoprim; TEC, teicoplanin; VAN, vancomycin; AMK, amikacin; CIP, ciprofloxacin; CFZ, cefazolin; CXM, cefuroxime; CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; SCF, cefoperazone-sulbactam; CST, colistin; ETP, ertapenem; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; TZP, piperacillin-tazobactam.